Scientists selected a gene that may have implications for the treatment of breast cancer
Researchers from Wroclaw Medical University selected a gene that may have implications for the treatment of breast cancer. The results are so promising that the application has already been sent to the patent office. Work on the project will continue.
Head of the Department of Histology and Embryology, Wroclaw Medical University, Prof. Piotr Dzięgiel told PAP that researchers selected one gene that could have implications for the efficacy of chemotherapy in breast cancer.
"This is just the tip of the iceberg, because we have submitted a patent application and we continue our research. There is still a long way to using our results in clinical trials" - added Piotr Dzięgiel.
The project "Expression profile of genes in determining breast cancer drug resistance" has been carried out since 2011 by Wroclaw Medical University, Wroclaw Research Centre EIT+ and Acumen Research Laboratories PTE LTD in Singapore.
Researchers compared cases responding well chemotherapy to cases responding poorly to this form of treatment. After examining more than 20,000 genes, one gene (prolactin iducible protein) was selected, which could be responsible for the effects of treatment.
"We have provided the lab in Singapore with research material that we obtained in cooperation with the Department of Cancer Pathology, Institute of Oncology in Kraków. Scientists from Singapore made the selection and then we confirmed these results" - said Prof. Dzięgiel.
Breast cancer is the most common cancer in women. In Poland, it accounts for 22 percent of all cancer cases among women.
According to the National Cancer Registry data, in 2010 it was diagnosed in about 16 thousand women, and 5,000 died because of it. It is most often detected between 50 and 64 years of age, still in the productive age.
ros/ abe/ krf/